1. Emerging Ablative and Transarterial Therapies for Pancreatic Cancer
- Author
-
Govindarajan Narayanan, Antonio Ucar, Arian Nasiri, Ripal T. Gandhi, Horacio Jose Asbun, Prasuna Inampudi, and Nicole M. Wilson
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Standard treatment ,Gastroenterology ,Cancer ,Irreversible electroporation ,medicine.disease ,Malignancy ,Radiation therapy ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Pancreatic cancer ,Internal medicine ,Medicine ,Adenocarcinoma ,Radiology, Nuclear Medicine and imaging ,Surgery ,business ,Pancreas - Abstract
Pancreatic adenocarcinoma is a highly aggressive malignancy with a poor prognosis secondary to late presentation with metastases, challenging resection, and limited alternative therapies. Standard treatment strategies for pancreatic cancer include surgery, chemotherapy, and radiation therapy. These options can extend survival and/or relieve symptoms but are seldom curative. Thermal ablative therapies have been utilized in pancreatic cancer mostly in an open surgical setting. Irreversible electroporation (IRE) is a nonthermal ablative option for pancreatic cancer that uses high voltage, low energy direct current to induce cell death. IRE technology has been shown to spare critical structures such as blood vessels and bile ducts. The safety and efficacy of the percutaneous IRE in Stage 3 pancreas cancer has been studied and there is currently a Food and Drug Administration approved, randomized, controlled trial, and registry enrolling patients in the United States. Recent animal studies have also demonstrated that the advantages of IRE may extend beyond the local tumor effect. In addition to this local ablative option, a phase 3 trial is studying a transarterial option in the management of pancreatic cancer.
- Published
- 2020
- Full Text
- View/download PDF